The company's technology also has applications in pharmaceutical R&D, partnering with companies like Janssen to accelerate drug development by generating evidence to inform clinical trial design and patient recruitment. Atropos' CEO, Brigham Hyde, emphasized the importance of providing quality, personalized evidence for decision making in healthcare. The company's mission is to ensure all patients and providers have access to such evidence.
Key takeaways:
- Atropos Health, a healthcare technology company, has raised $33 million in a Series B funding round with investments from McKesson, Merck, and Cencora Ventures.
- The company plans to use the new capital to expand its operations and focus on initiatives such as launching in life sciences, expanding channel partnerships in value-based care and oncology, and growing its evidence network of data partners.
- Atropos’ core technology, Geneva OS, uses AI and automation to rapidly generate clinical-grade evidence from real-world data, aiming to close the 'evidence gap' in healthcare.
- The company has partnered with pharmaceutical giants like Janssen to accelerate drug development by generating evidence to inform clinical trial design, patient recruitment, and more.